Akari Therapeutics
AKTX
10 hedge funds and large institutions have $3.7M invested in Akari Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 → 10 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
26% less capital invested
Capital invested by funds: $5.03M → $3.7M (-$1.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$191K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$41.3K |
| 3 |
VF
Virtu Financial
New York
|
+$38.3K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$29.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$6.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$699K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$266K |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
Hikari Power
Tokyo,
Japan
| $2.56M | +$191K | +125 | +7% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $773K | – | – | – |
|
3
Renaissance Technologies
New York
| $232K | +$1.53K | +1 | +0.6% |
|
|
VF
4
Virtu Financial
New York
| $53K | +$38.3K | +25 | +179% |
|
|
ARTA
5
A.R.T. Advisors
New York
| $36K | +$41.3K | +27 | New |
|
|
6
HighTower Advisors
Chicago,
Illinois
| $25K | +$29.1K | +19 | New |
|
|
TC
7
Truvestments Capital
Sarasota,
Florida
| $6K | – | – | – |
|
|
8
Bank of America
Charlotte,
North Carolina
| $5K | +$6.12K | +4 | New |
|
9
UBS Group
Zurich,
Switzerland
| $4K | +$4.59K | +3 | New |
|
10
Morgan Stanley
New York
| $2K | +$1.53K | +1 | +100% |
|
|
VC
11
Vivo Capital
Palo Alto,
California
| – | -$699K | -432 | Closed |
|
|
12
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$266K | -165 | Closed |
|
|
13
Parallax Volatility Advisers
San Francisco,
California
| – | -$15K | -9 | Closed |
|
AKTX Hedge Fund Activity: Q3 2019 in Review
10 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2019, worth a combined $3.7M — down 26% from $5.03M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AKTX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Hikari Power, adding an estimated $191K. The largest seller was Vivo Capital, exiting entirely with an estimated $699K sold.
- 10 institutional investors held Akari Therapeutics (AKTX) as of Q3 2019, up from 9 in Q2 2019.
- Funds reported $3.7M of Akari Therapeutics stock for Q3 2019, down 26% quarter-over-quarter.
- 4 funds opened new Akari Therapeutics positions in Q3 2019 and 3 closed out, a net change of +1 holder.
- The largest Akari Therapeutics buyer in Q3 2019 was Hikari Power, an estimated $191K added.
- The largest Akari Therapeutics seller in Q3 2019 was Vivo Capital, an estimated $699K sold.
Based on aggregated 13F filings for Q3 2019.